News & Insights Search

The US Food and Drug Administration (FDA) could take additional steps to more successfully implement disclosures of complete response letters (CRLs) to the public, experts argued in a recent paper published in the Journal of Law and the Biosciences.

Industry and patient groups have asked the US Food and Drug Administration (FDA) to make several changes to its revised draft guidance on master protocols for drugs and biological products. Additionally, two industry groups pushed for greater harmonization with global regulators, while a group representing clinical trial sites questioned the practicality of the guidance when it comes to site-level operations.

The Indian government has simplified the regulatory framework for outsourced sterilization of medical devices as part of a push to support businesses.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. According to news reports, the Trump administration may create two more FDA executive positions in a possible bid to exert more control over the agency; FDA approved several first-of-its-kind treatments, including a drug that was approved well ahead of its decision date and a wearable device that tracks ketones and glucose levels.

The US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) has issued an untitled letter to Alar Pharmaceuticals, accusing the company of making misleading claims regarding the safety and effectiveness of ALA-3000 (ketamine pamoate), its investigational new drug for treatment-resistant depression (TRD).

Drug manufacturing process models represent a "growing area" of scientific development and are increasingly being utilized in new drug applications (NDAs), biologics license applications (BLAs), and supplements to these applications, according to a recent review by US Food and Drug Administration (FDA) officials.

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its pharmacovigilance procedures guidance with new advice about periodic safety update reports (PSURs).

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Pharmaceutical industry groups argue that the US Food and Drug Administration (FDA) should provide clearer guidance on the role of qualified research institutions (QRIs) in its proposed expedited investigational new drug pilot program, which is intended to reduce the time it takes to get drug candidates into first-in-human (FIH) trials.